[HTML] nih.gov

Quantitative [18F]FMISO PET Imaging Shows Reduction of Hypoxia Following Trastuzumab in a Murine Model of HER2+ Breast Cancer

AG Sorace, AK Syed, SL Barnes, CC Quarles… - Molecular imaging and …, 2017 - Springer
AG Sorace, AK Syed, SL Barnes, CC Quarles, V Sanchez, H Kang, TE Yankeelov
Molecular imaging and biology, 2017•Springer
Purpose Evaluation of [18 F] fluoromisonidazole ([18 F] FMISO)-positron emission
tomography (PET) imaging as a metric for evaluating early response to trastuzumab therapy
with histological validation in a murine model of HER2+ breast cancer. Procedures Mice with
BT474, HER2+ tumors, were imaged with [18 F] FMISO-PET during trastuzumab therapy.
Pimonidazole staining was used to confirm hypoxia from imaging. Results [18 F] FMISO-PET
indicated significant decreases in hypoxia beginning on day 3 (P< 0.01) prior to changes in …
Purpose
Evaluation of [18F]fluoromisonidazole ([18F]FMISO)-positron emission tomography (PET) imaging as a metric for evaluating early response to trastuzumab therapy with histological validation in a murine model of HER2+ breast cancer.
Procedures
Mice with BT474, HER2+ tumors, were imaged with [18F]FMISO-PET during trastuzumab therapy. Pimonidazole staining was used to confirm hypoxia from imaging.
Results
[18F]FMISO-PET indicated significant decreases in hypoxia beginning on day 3 (P < 0.01) prior to changes in tumor size. These results were confirmed with pimonidazole staining on day 7 (P < 0.01); additionally, there was a significant positive linear correlation between histology and PET imaging (r 2  = 0.85).
Conclusions
[18F]FMISO-PET is a clinically relevant modality which provides the opportunity to (1) predict response to HER2+ therapy before changes in tumor size and (2) identify decreases in hypoxia which has the potential to guide subsequent therapy.
Springer
展开收起
被引用次数：34 相关文章 所有 11 个版本
以上显示的是最相近的搜索结果。 查看全部搜索结果